Bitopic ligands represent a powerful strategy to modulate G protein-coupled receptors by simultaneously engaging orthosteric and allosteric binding sites. In this study, we designed and synthesized two series of dequalinium-based hybrid ligands targeting muscarinic acetylcholine receptors (mAChRs), in which a dequalinium fragment was linked through polymethylene spacers of variable length either to the orthosteric superagonist iperoxo (Deq-X-Iper, 5a-c) or to a molecular portion of the allosteric inverse agonist W84 (Deq-X-W84, 6a-c). Equilibrium and kinetic binding studies at human mAChR subtypes (hM1-hM5) revealed good to high affinity for all compounds and a consistent bitopic mode of action, supported by a spacer-length-dependent enhancement of both orthosteric and allosteric interactions. Functional assays showed that Deq-X-W84 derivatives act as unselective muscarinic antagonists, whereas Deq-X-Iper ligands behave as agonists. Notably, the latter displayed probe-dependent negative allosteric modulation of acetylcholine-induced ERK1/2 phosphorylation at the hM4 receptor, revealing an unexpected functional profile. Docking and molecular dynamics simulations provided a structural rationale for these findings, highlighting stable bitopic binding poses and linker-dependent optimization of receptor contacts. Overall, these results demonstrate that dequalinium-based bitopic ligands can encode distinct functional outcomes at muscarinic receptors, offering new insights into the design of ligands with tailored signaling profiles.
Dequalinium-based bitopic ligands uncover distinct pharmacological modulation of muscarinic receptors / R. Ferrisi, S. Vittorio, S. Morando, C. Giorgio, N. Brivio, E. Cortese, A. Colleoni, C. Papotto, C. Matera, M.D. Amici, E. Barocelli, G. Vistoli, R. Matucci, C. Dallanoce. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - 250:Pt 2(2026 Aug), pp. 118019.1-118019.14. [10.1016/j.bcp.2026.118019]
Dequalinium-based bitopic ligands uncover distinct pharmacological modulation of muscarinic receptors
R. FerrisiPrimo
;S. VittorioSecondo
;A. Colleoni;C. Papotto;C. Matera;M.D. Amici;G. Vistoli;C. Dallanoce
Ultimo
2026
Abstract
Bitopic ligands represent a powerful strategy to modulate G protein-coupled receptors by simultaneously engaging orthosteric and allosteric binding sites. In this study, we designed and synthesized two series of dequalinium-based hybrid ligands targeting muscarinic acetylcholine receptors (mAChRs), in which a dequalinium fragment was linked through polymethylene spacers of variable length either to the orthosteric superagonist iperoxo (Deq-X-Iper, 5a-c) or to a molecular portion of the allosteric inverse agonist W84 (Deq-X-W84, 6a-c). Equilibrium and kinetic binding studies at human mAChR subtypes (hM1-hM5) revealed good to high affinity for all compounds and a consistent bitopic mode of action, supported by a spacer-length-dependent enhancement of both orthosteric and allosteric interactions. Functional assays showed that Deq-X-W84 derivatives act as unselective muscarinic antagonists, whereas Deq-X-Iper ligands behave as agonists. Notably, the latter displayed probe-dependent negative allosteric modulation of acetylcholine-induced ERK1/2 phosphorylation at the hM4 receptor, revealing an unexpected functional profile. Docking and molecular dynamics simulations provided a structural rationale for these findings, highlighting stable bitopic binding poses and linker-dependent optimization of receptor contacts. Overall, these results demonstrate that dequalinium-based bitopic ligands can encode distinct functional outcomes at muscarinic receptors, offering new insights into the design of ligands with tailored signaling profiles.| File | Dimensione | Formato | |
|---|---|---|---|
|
Biochemical Pharmacology 250 (2026) 118019.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
8.58 MB
Formato
Adobe PDF
|
8.58 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Journal Pre-proofs DOI 10.1016j.bcp.2026.118019.pdf
embargo fino al 01/09/2027
Descrizione: Pre-proofs
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Licenza:
Creative commons
Dimensione
3.56 MB
Formato
Adobe PDF
|
3.56 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.




